Wall Street analyst estimates for Align Technology, Inc. (ALGN): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry.
Consensus price target
$192.50 (+17% vs price $164.90)
between $162.00 and $215.00 · 4 targets published in the last quarter
Closing price, Nov 4
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $4.1B | $4.1B – $4.2B | $11.14 | 7 |
| 2027E | $4.2B | $4.1B – $4.4B | $12.30 | 10 |
| 2028E | $4.4B | $4.2B – $4.7B | $13.41 | 6 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 23 |
| Hold | 8 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 33 |
| Avg rating (−2 sell to +2 buy) | 0.64 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-03 | $3.15 | ||
| 2026-10-28 | $2.80 | $2.77 | +1.1% |
| 2026-07-29 | $2.64 | $2.62 | +0.8% |
| 2026-04-29 | $2.58 | $2.30 | +12.2% |
| 2026-02-04 | $3.29 | $2.99 | +10.0% |
| 2025-10-29 | $2.61 | $2.40 | +8.8% |
| 2025-07-30 | $2.49 | $2.57 | -3.1% |
| 2025-04-30 | $2.13 | $1.99 | +7.0% |
Valuation Ratios
| P/E Ratio | 23.97 |
| Price / Book | 2.72 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.08B | $1.47B | $1.97B | $2.41B | $2.47B | $3.95B | $3.73B | $3.86B | $4.00B | $4.03B |
| Cost of Revenue | $264.6M | $356.5M | $518.6M | $662.9M | $708.7M | $1.02B | $1.10B | $1.16B | $1.20B | $1.28B |
| Gross Profit | $815.3M | $1.12B | $1.45B | $1.74B | $1.76B | $2.94B | $2.63B | $2.71B | $2.80B | $2.76B |
| Research & Development | $75.7M | $97.6M | $128.9M | $157.4M | $175.3M | $250.3M | $305.3M | $346.8M | $364.2M | $369.9M |
| Selling, General & Admin | $490.7M | $665.8M | $852.4M | $1.07B | $1.20B | $1.71B | $1.67B | $1.70B | $1.76B | $1.76B |
| Operating Expenses | $566.4M | $763.3M | $981.3M | $1.20B | $1.38B | $1.96B | $1.99B | $2.06B | $2.19B | $2.14B |
| Operating Income | $248.9M | $353.6M | $466.6M | $542.5M | $387.2M | $976.4M | $642.6M | $643.3M | $607.6M | $616.2M |
| EBITDA | $272.9M | $391.4M | $521.3M | $593.5M | $480.7M | $1.12B | $779.8M | $799.1M | $816.8M | $822.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | $242.6M | $364.8M | $458.0M | $555.1M | $378.9M | $1.01B | $599.1M | $641.2M | $609.0M | $585.3M |
| Income Tax | $51.2M | $130.2M | $57.7M | $112.3M | -$1.40B | $240.4M | $237.5M | $196.2M | $187.6M | $174.9M |
| Net Income | $189.7M | $231.4M | $400.2M | $442.8M | $1.78B | $772.0M | $361.6M | $445.1M | $421.4M | $410.4M |
| EPS | $2.38 | $2.89 | $5.00 | $5.57 | $22.55 | $9.78 | $4.62 | $5.82 | $5.63 | $5.66 |
| EPS (Diluted) | $2.33 | $2.83 | $4.92 | $5.53 | $22.41 | $9.69 | $4.61 | $5.81 | $5.62 | $5.65 |
| Shares Outstanding (Diluted) | 81.5 M | 81.8 M | 81.4 M | 80.1 M | 79.2 M | 79.7 M | 78.4 M | 76.6 M | 75.0 M | 72.6 M |
Price
| Price | $164.90 (closing price, November 4, 2026) |
| Market Cap | $11.7B |
| Exchange | NASDAQ |
| Country | US |
Related companies: XRAY · NVST · ABT · MDT · SYK · 0Y6X.L · 0R2S.L · BSX
Explore sector: Healthcare · Medical - Devices
More sections of ALGN: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks